

RESEARCH ARTICLE

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod

Zi-Ye Song¹, Ryo Yamasaki², Yuji Kawano¹, Shinya Sato¹, Katsuhisa Masaki¹, Satoshi Yoshimura¹, Dai Matsuse¹, Hiroyuki Murai¹, Takuya Matsushita¹, Jun-ichi Kira^{1*}

1 Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, **2** Department of Neurological Therapeutics, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

* kira@neuro.med.kyushu-u.ac.jp



Abstract

Background

Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated with MS relapse on fingolimod.

Methods/Principal Findings

Blood samples successively collected from 23 relapsing-remitting MS patients before and during fingolimod therapy (0.5 mg/day) for 12 months and 18 healthy controls (HCs) were analysed for T cell subsets by flow cytometry. In MS patients, the percentages of central memory T (CCR7⁺CD45RO⁺) cells (TCM) and naïve T (CCR7⁺CD45RO⁻) cells decreased significantly, while those of effector memory T (CCR7⁻CD45RA⁻) and suppressor precursor T (CD28⁻) cells increased in both CD4⁺T and CD8⁺T cells from 2 weeks to 12 months during fingolimod therapy. The percentages of regulatory T (CD4⁺CD25^{high}CD127^{low}) cells in CD4⁺T cells and CCR7⁻CD45RA⁺T cells in CD8⁺T cells also increased significantly. Eight relapsed patients demonstrated greater percentages of CD4⁺TCM than 15 non-relapsed patients at 3 and 6 months ($p=0.0051$ and $p=0.0088$, respectively). The IL17-, IL9-, and IL4-producing CD4⁺T cell percentages were significantly higher at pre-treatment in MS patients compared with HCs ($p<0.01$ for all), while the IL17-producing CD4⁺T cell percentages tended to show a transient increase at 2 weeks of fingolimod therapy ($p^{corr}=0.0834$).

Conclusions

The CD4⁺TCM percentages at 2 weeks to 12 months during fingolimod therapy are related to relapse.

OPEN ACCESS

Citation: Song Z-Y, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S, et al. (2015) Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod. PLoS ONE 10(4): e0124923. doi:10.1371/journal.pone.0124923

Academic Editor: Akio Suzumura, Research Inst. of Environmental Med., Nagoya Univ., JAPAN

Received: December 2, 2014

Accepted: March 10, 2015

Published: April 28, 2015

Copyright: © 2015 Song et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data (without personal informations) are within the paper and its Supporting Information files. Complete data are also available from the Kyushu University Institutional Data Access / Ethics Committee for researchers who meet the criteria for access to confidential data.

Funding: This work was supported in part by Health and Labour Sciences Research Grants on Intractable Diseases (H24-Nanchitou (Nan)-Ippan-055 and H23-Nanchi-Ippan-017) from the Ministry of Health, Labour and Welfare, Japan, and by a Grant-in-Aid for Scientific Research B (No. 25293204), a Grant-in-Aid

for Exploratory Research (No. 25670423), and a Grant-in-Aid for Scientific Research on Innovative Areas (No. 25117012) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. Ryo Yamasaki has received research support from Bayer Schering Pharma, Biogen Idec, Novartis Pharma, and Mitsubishi Tanabe Pharma. Takuya Matsushita has received speaker honoraria from Bayer Schering Pharma, Biogen Idec, and Pfizer and receives research support from Bayer Schering Pharma, Biogen Idec, Novartis Pharma, Mitsubishi Tanabe Pharma, the Ministry of Health, Labour and Welfare of Japan, the Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Kaibara Morikazu Medical Science Promotion Foundation, Japan. Jun-ichi Kira has received honoraria from Biogen Idec Japan, Novartis Pharma Japan, and Mitsubishi Tanabe Pharma Corporation. He is funded by a Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan, and grants from the Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science and Technology, Japan, Pfizer Japan, and the Japan Blood Products Organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Jun-ichi Kira serves as an editorial board member of *Clinical and Experimental Neuroimmunology*, *Multiple Sclerosis Journal*, *Multiple Sclerosis and Related Disorders*, *BMC Medicine*, *PLOS ONE*, *Expert Review of Neurotherapeutics*, *Intractable and Rare Diseases Research*, *The Scientific World Journal*, and *Journal of the Neurological Sciences*. The authors have received support from the following commercial sources: Bayer Schering Pharma, Biogen Idec, Novartis Pharma, Mitsubishi Tanabe Pharma, Pfizer, and the Japan Blood Products Organization. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Introduction

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and is assumed to be an autoimmune disease targeting myelin [1]. Fingolimod efficiently reduces MS relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) receptors [2,3], which is consistent with findings in an animal model of MS that fingolimod successfully reduced the infiltration of myelin antigen-specific CD4⁺T cells into inflammatory sites in experimental autoimmune encephalomyelitis [4]. Fingolimod traps CD45RO⁺ central memory T cells (TCM) and naïve T cells expressing homing receptors for lymph nodes, CCR7 and CD62L, within lymph nodes [5]. The drug is supposed to exert its effects by inhibiting recirculation of TCM, which include autoreactive T cells [6]. Although fingolimod was also found to be beneficial in a controlled trial for human renal transplantation [7], its effects have not been examined for any other autoimmune diseases in large-scale clinical trials.

MS is now assumed to be a T helper 1 (Th1)/Th17-mediated autoimmune disease [1]. Some authors reported a decrease in IL17-positive cells in MS patients on fingolimod 1.25 mg once daily at the long-term therapy stage, but not on IFN β [8], while others reported an increase in IL17-producing cells in a considerable fraction of MS patients on fingolimod 0.5 mg once daily at the short-term treatment stage [9]. In addition, effector memory T cells (TEM) without CCR7, which reside in non-lymphoid organs and mainly comprise IFN γ -producing Th1 cells protecting against infection, were found to show a relative increase during fingolimod therapy [7], while other authors reported TEM as the principal IL17-producing T cells [10]. Thus, the short-term and long-term effects of fingolimod on Th17 cells at an ordinary dosage (0.5 mg/day) remain to be elucidated. Therefore, we aimed to clarify the alterations in peripheral blood T cell subsets during short-term and long-term treatment periods, which are associated with therapeutic efficacy or treatment failure including suboptimal responses during fingolimod therapy.

Materials and Methods

Patients and control subjects

Venous blood samples were obtained from 18 healthy controls (HCs) (12 females and 6 males; mean age \pm SD, 41.2 \pm 12.2 years) and 23 relapsing-remitting MS patients (15 females and 8 males; mean age \pm SD, 42.3 \pm 12.5 years) who were started on fingolimod therapy between 2012 and 2014 at Kyushu University Hospital after informed consent was obtained (Table 1). In the latter, blood was withdrawn before and at 2 weeks and 1, 2, 3, 6, and 12 months after initiation of fingolimod 0.5 mg once daily. MS was diagnosed based on the 2005 revised McDonald criteria for MS [11] and all patients were seronegative for anti-aquaporin-4 (AQP4) antibodies [12,13]. Ten patients had neither immunomodulatory drugs nor corticosteroids within 3 months before the initiation of fingolimod, two had IFN β -1b until 10 days and 1 day before fingolimod initiation, respectively, one had IFN β -1a until 14 days before, and nine had prednisolone until 1 day before. All MS patients underwent a neurological examination at our outpatient clinic at 2–4-week intervals and were evaluated by the Expanded Disability Status Scale of Kurtzke (EDSS) [14] with calculation of the Progression Index [15], and observed for the emergence of clinical relapse. Clinical relapse was defined as the appearance of new symptoms or return of old symptoms for a period of 24 hours or more in the absence of a change in the core body temperature or infection [16]. Brain and spinal cord MRI was performed at 6 and 12 months after initiation of fingolimod to determine the presence of new/enlarging T2 lesions and gadolinium-enhanced T1 lesions (MRI relapse) [16]. All MRI studies were

Table 1. Demographic features of the subjects.

	HCs	MS PT	MS during fingolimod treatment for 12 months Relapsed patient	Non-relapsed patient
Sex (male: female)	6: 12	8: 15	3: 5	5: 10
Age at examination (mean ± SD, years)	41.2 ± 12.2	42.3 ± 12.5	35.6 ± 13.3	40.0 ± 11.9
Age at Onset (mean ± SD, years)	NA	28.9 ± 12.4	28.1 ± 12.4	28.7 ± 12.8
Disease duration (mean±SD, years)	NA	11.2 ± 9.7	7.3 ± 8.1	13.2 ± 10.1
Annualised relapse rate (mean ± SD, /years)	NA	3.3 ± 3.0	2.9 ± 3.0	3.5 ± 3.1
EDSS scores before fingolimod treatment (mean ± SD)	NA	2.8 ± 2.1	2.5 ± 2.3	3.2 ± 2.1
Progression Index (mean ± SD)	NA	0.6 ± 1.0	0.9 ± 1.6	0.4 ± 0.4

Abbreviations: HCs = healthy controls; MS PT = multiple sclerosis at pre-treatment; EDSS = Expanded Disability Status Scale of Kurtzke.

doi:10.1371/journal.pone.0124923.t001

performed using a 1.5 T unit (Magnetom Vision and Symphony; Siemens Medical Systems, Erlangen, Germany) as previously described [17]. This study was approved by the Kyushu University Hospital Ethics Committee. All individuals involved in this study signed a written informed consent form (Approval Number: 575–03).

Antibodies and flow cytometry

T cells were analysed in whole blood specimens using the following antibodies from Miltenyi Biotec (Auburn, CA): anti-human CD3-VioBlue (BW264/56, MACS), CD4-APC (M-T466, MACS), CD8-APC (BW135/80, MACS), CD45RO-FITC (UCHL1, MACS), CD45RA-APC-Vio770 (T6D11, MACS), CD127-FITC (MB15-18C9, MACS), CD25-PE (4E3, MACS), CCR7-PE (FR11-11E8, MACS), CD8-PE (BW135/80, MACS), CD4-FITC (M-T466, MACS), and CD28-APC (15E8, MACS). The following isotype controls from Miltenyi Biotec were also used: anti-mouse IgG1-PE (IS5-21F5, MACS), IgG1-APC (IS5-21F5, MACS), IgG1-FITC (IS5-21F5, MACS), IgG2a-APC (S43.10, MACS), IgG2a-VioBlue (S43.10, MACS), IgG2a-PE (S43.10, MACS), IgG2a-FITC (S43.10, MACS), IgG2b-APC-Vio770 (IS6-11E5.11, MACS), IgG2b-PE (IS6-11E5.11, MACS), and IgG2b-FITC (IS6-11E5.11, MACS). Specific cytokine-producing cells and chemokine receptor-positive cells were analysed using the following antibodies: anti-human CD4-APC (M-T466, MACS; Miltenyi Biotec), CD8-VioBlue (BW135/80, MACS; Miltenyi Biotec), IFN γ -FITC (25723.11; BD Biosciences, San Jose, CA), IL17-PE (BL168; Biolegend, San Diego, CA), IL4-FITC (MP4-25D2; Biolegend), and IL9-PE (AH9R7; Biolegend). Peripheral blood mononuclear cells (PBMCs) were isolated with Lymphoprep Tubes (AXIS-SHIELD Poc AS, Oslo, Norway). For intracellular cytokine detection, PBMCs were stimulated with phorbol 12-myristate 13-acetate (10 ng/ml) and ionomycin (1 μ g/ml) (both from Enzo Life Sciences, Plymouth Meeting, PA) in the presence of brefeldin A (Sigma-Aldrich, St. Louis, MO) for 4 h at 37°C in 5% CO $_2$, fixed, and permeabilised with BD FACS lysing solution and BD FACS permeabilising solution (BD Biosciences) according to the manufacturer’s instructions. Data were acquired using a FACScan flow cytometer (MACSQuant Analyzer; Miltenyi Biotec) according to standard procedures for whole blood samples and PBMCs, as described previously [18,19]. Naïve T (CCR7 $^+$ CD45RO $^-$) cells, TCM (CCR7 $^+$ CD45RO $^+$), TEM (CCR7 $^-$ CD45RA $^-$), CD8 $^+$ CD45RA $^+$ effector memory T (CD8 $^+$ CCR7 $^-$ CD45RA $^+$) cells (TEMRA), regulatory T (CD4 $^+$ CD25 $^{\text{high}}$ CD127 $^{\text{low}}$) cells (Treg), and suppressor precursor T (CD28 $^-$) cells (Ts) were measured in all 23 patients in S1 Fig, while IFN γ -, IL17-, IL9-, and IL4-producing cells were analysed in 16 patients.

Statistical analysis

Demographic features between MS patients and HCs and between MS patients with and without relapse on fingolimod were compared by the Mann—Whitney U test, except for the sex ratio compared by Fisher's test. T cell counts and subset percentages between MS patients and HCs, between pre-treatment and post-treatment values in MS patients, and between MS patients with and without relapse on fingolimod were compared by the Mann—Whitney U test. For independent multiple comparisons, uncorrected p (p^{uncorr}) values were multiplied by the number of comparisons to calculate corrected p (p^{corr}) values (Bonferroni—Dunn's correction). Values of $p < 0.05$ were considered to indicate statistical significance.

Results

Demographic features and treatment response to fingolimod

During fingolimod therapy, four patients had mild liver dysfunction and three patients had lymphopenia (less than 200 / μ l), all of which recovered after cessation of the drug or symptomatic treatment. Also during fingolimod therapy, two patients had clinical relapses (both at 3 months after initiation of the drug) and six patients had new gadolinium-enhanced lesions on T1-weighted MRI or new/enlarging lesions on T2-weighted images at 6 or 12 months after initiation of the drug. These eight patients were classified as a relapsed group, while the remaining 15 patients were classified as a non-relapsed group. Although the relapsed patients had a shorter disease duration and higher Progression Index than the non-relapsed patients, there were no significant differences in any of the demographic features examined between the relapsed and non-relapsed patients ([Table 1](#)).

Comparisons of T cell subsets between MS patients at pre-treatment and HCs

There were no significant differences in the counts of lymphocytes, CD4⁺T cells, and CD8⁺T cells and the percentages of CD4⁺T cells between the MS patients at pre-treatment and HCs, while the percentage of CD8⁺T cells was significantly lower in MS patients than in HCs ($p < 0.05$) ([Fig 1A–1C](#)). In addition, there were no significant differences in the percentages of naïve T cells, TCM, TEM, Treg, and Ts in CD4⁺T cells and naïve T cells, TCM, TEM, TEMRA, and Ts in CD8⁺T cells between the MS patients at pre-treatment and HCs ([Fig 2A](#) and [2B](#)).

Alterations in T cell subsets during fingolimod therapy

The total lymphocyte counts were markedly decreased from 2 weeks until 12 months after initiation of fingolimod ([Fig 1A](#)), and the absolute counts and percentages of CD4⁺T cells and the counts of CD8⁺T cells were also decreased ([Fig 1B](#) and [1C](#)). The absolute counts of TCM, naïve T cells, and TEM in both CD4⁺T and CD8⁺T cells and Treg in CD4⁺T cells decreased significantly from 2 weeks to 12 months compared with the pre-treatment levels ($p < 0.0001$ for all), as shown in [S2 Fig](#).

In CD4⁺T cells, the percentages of TCM and naïve T cells decreased significantly from 2 weeks to 12 months compared with the pre-treatment levels ($p < 0.0001$ for all), while the TEM and Ts percentages increased from 2 weeks to 12 months compared with the pre-treatment levels ($p < 0.0001$ for all) and the Treg percentages also increased from 2 weeks to 1 month ($p < 0.05$) ([Fig 2A](#)). In CD8⁺T cells, the percentages of naïve T cells and TCM decreased significantly from 2 weeks to 12 months compared with the pre-treatment levels, while the TEMRA and Ts percentages increased from 2 weeks to 12 months ($p < 0.0001$ for all) ([Fig 2B](#)). However, the TEM percentages in CD8⁺T cells showed no significant changes.




Fig 1. Counts of lymphocytes, CD4⁺T, and CD8⁺T cells are decreased from 2 weeks. Effects of fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percentages of CD4⁺T (B) and CD8⁺T (C) cells in lymphocytes of healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. The numbers examined at each time point were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate the mean values. W = week; M = month. *** $p < 0.0001$, * $p < 0.05$.

doi:10.1371/journal.pone.0124923.g001

Comparisons of specific cytokine-producing T cell percentages between MS patients at pre-treatment and HCs

The percentages of IL17⁻, IL9⁻, and IL4-producing cells in CD4⁺T cells were significantly higher in MS patients than in HCs ($p < 0.01$ for all), and the percentages of IFN γ ⁻, IL17⁻, IL9⁻, and IL4-producing cells in CD8⁺T cells were also significantly higher in MS patients than in HCs ($p < 0.05$, $p < 0.01$, $p < 0.01$, and $p < 0.05$, respectively) (Fig 3). These trends were observed in IL17⁻, IL9⁻, and IL4-producing CD4⁺T and CD8⁺T cells in the MS patients, irrespective of whether they had IFN β or corticosteroids within 3 months of initiation of fingolimod, as shown in S3 Fig. However, the increases in IFN γ -producing CD4⁺T and CD8⁺T cells at pre-treatment were only significant in the MS patients without IFN β or corticosteroids.

Alterations in specific cytokine-producing T cell percentages during fingolimod therapy

The percentages of IFN γ -producing cells in both CD4⁺T and CD8⁺T cells and those of IL17-producing cells in CD4⁺T cells increased transiently at 2 weeks after initiation of





Fig 2. The percentages of T cell subsets show significant changes from 2 weeks. Effects of fingolimod on phenotypically distinct CD4⁺T (A) and CD8⁺T (B) cell subpopulations in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. Naïve = naïve T cells (CCR7⁺CD45RO⁺); TCM = central memory T cells (CCR7⁺CD45RO⁺); TEM = effector memory T cells (CCR7⁺CD45RA⁺); Treg = regulatory T cells (CD4⁺CD25^{high}CD127^{low}); Ts = suppressor precursor T cells (CD28⁺); TEMRA = CD8⁺CD45RA⁺effector memory T cells (CD8⁺CCR7⁺CD45RA⁺). The numbers examined at each time point were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate the mean values. W = week; M = month. ****p*<0.0001, ***p*<0.01, **p*<0.05.




doi:10.1371/journal.pone.0124923.g002

fingolimod ($p^{uncorr} < 0.05$ for all, but not significant after correction for multiple comparisons except that IL17-producing CD4⁺T cells showed an increased tendency at 2 weeks, $p^{corr} = 0.0834$), and thereafter decreased gradually to the pre-treatment levels after 3 months (Fig 3). These changes were observed regardless of prior treatment with IFN γ or prednisolone (data not shown). In contrast, IL17-producing CD8⁺T cells, and IL4- and IL9-producing CD4⁺T and CD8⁺T cells showed no such transient increases after the introduction of fingolimod. However,


A Percentages of IFN γ -producing cell



B Percentages of IL17-producing cell



C Percentages of IL9-producing cell



D Percentages of IL4-producing cell






Fig 3. The IL17-, IL9-, and IL4-producing cells are higher in MS patients than in HCs. Effects of fingolimod on IFN γ - (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4⁺T and CD8⁺T cells in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. The numbers examined at each time point were: HC = 9, and MS PT = 16, 2W = 12, 1M = 12, 2M = 11, 3M = 12, 6M = 7, 12M = 11. The horizontal bars indicate the mean values. Open diamonds = MS patients with relapse during fingolimod therapy ($n = 2$); closed circles = MS patients without relapse during the therapy ($n = 14$). W = week; M = month. $**p < 0.01$, $*p < 0.05$.

doi:10.1371/journal.pone.0124923.g003

the absolute counts of all cytokine-producing T cells in CD4⁺T cells decreased significantly from 2 weeks to 12 months compared with the pre-treatment levels ($p^{corr} < 0.05$ for all), as shown in [S4 Fig](#).

Correlations of alterations in distinct T cell subsets and specific cytokine-producing T cells during fingolimod therapy with treatment response


When the relapsed and non-relapsed MS patients were compared, only the percentages of CD4⁺TCM differed significantly between the two groups. Specifically, the relapsed patients had significantly greater percentages of CD4⁺TCM than the non-relapsed patients at 3 and 6 months ($p = 0.0051$ and $p = 0.0088$, respectively) ([Fig 4](#)).

Discussion


This study is the first to successively assess the dynamics of T cell subsets from 2 weeks up to 12 months of fingolimod therapy in MS patients. Although selection bias was not completely eliminated, no selection was made on referral to our clinic for initiation of fingolimod treatment. In addition, clinical and MRI relapses were seen in 8.7% and 26.1% of our patients, respectively, at 0–12 months. These findings are consistent with the observations in a Japanese clinical trial of fingolimod 0.5 mg once daily, in which clinical relapses occurred in 15.6% at 0–6 months and 6.7% at 7–12 months, while gadolinium-enhanced T1 lesions appeared in 22.2% at 0–6 months and 15.6% at 7–12 months and new/enlarging T2 lesions appeared in 33.3% at 0–6 months and 13.3% at 7–12 months [20]. Therefore, we believe that the recruitment of MS patients did not severely distort our findings.

The reductions in TCM and naïve T cells in both CD4⁺T and CD8⁺T cells in peripheral blood occurred very rapidly and continued for as long as fingolimod was administered. Interestingly, among the T cell subsets showing significant alterations during fingolimod therapy, only the CD4⁺TCM percentages were associated with MS relapse, although the pre-treatment TCM percentages in CD4⁺T cells did not differ significantly between the relapsed and non-relapsed patients, suggesting a critical role of CD4⁺TCM cells in MS relapse. The relapsed patients had a shorter disease duration and higher Progression Index than the non-relapsed patients in our study, but the differences were not significant, possibly because of the small sample size. Thus, MS patients in the early course, who are presumed to have high inflammatory disease activity, may tend to show a suboptimal response to fingolimod 0.5 mg once daily because of an insufficient decrease in CD4⁺TCM cells. Therefore, careful observation of the clinical and MRI disease activity may be required when fingolimod is introduced in MS patients with shorter disease duration and high disease activity. The present findings indicate that peripheral blood CD4⁺TCM cell percentages during fingolimod therapy may have a predictive value for relapse at least during the first year. However, as the present study involved a relatively small cohort, a large-scale confirmatory study will be necessary to establish TCM frequency as a potential biomarker for the relapse propensity of MS patients on fingolimod treatment.

The increased pre-treatment percentages of IL17-producing CD4⁺T and CD8⁺T cells in MS patients, especially in MS patients without IFN β or corticosteroids, are consistent with a previous study showing that peripheral blood Th17 cells increase in Western MS patients [21]. These observations collectively suggest pathogenic roles of IL17-producing T cells in MS. In our study, the IL17-producing CD4⁺T cell percentage showed a transient increase in the very early course of fingolimod therapy, which is partly compatible with the increase in IL17-producing cells observed in a short-term study of fingolimod [9]. This increase may be explained by a relative increase in TEM, which contain both Th1 and Th17 cells [10], while the absence of replenishment of Th1 and Th17 cells by naïve T cells that are continuously trapped in lymph



A TCM in CD4⁺T cells



B TEM in CD4⁺T cells




Fig 4. The relapsed patients have greater percentages of CD4⁺TCM at 3 and 6 months. Comparisons of TCM (A) and TEM (B) percentages in CD4⁺T cells at pre-treatment (MS PT) and the indicated periods of fingolimod treatment between MS patients with (open diamonds) and without (closed circles) relapse during the therapy. Box-whisker plots are shown. W = week; M = month.

doi:10.1371/journal.pone.0124923.g004

nodes may limit the persistence of the increase [6,22]. Importantly, this transient increase in the IL17-producing cell percentage was not associated with the development of relapse, at least in anti-AQP4 antibody-seronegative MS patients. In contrast, unexpected relapse was reported to occur in the early course of anti-AQP4 antibody-positive patients with neuromyelitis optica

(NMO) [19,23] and tumefactive MS patients [24,25]. As an increase in IL17 in CSF was observed in NMO patients at relapse [26–28], it is possible that the transient increase in the IL17-producing cell percentage may play a role in these conditions with fingolimod therapy.

Compared with HCs, IFN γ -, IL4-, and IL9-producing CD4⁺T and CD8⁺T cells were increased in MS patients at pre-treatment, especially in the MS patients without IFN γ or corticosteroids. Increases in IFN γ -producing CD4⁺T and CD8⁺T cells were previously reported in Western and Asian MS patients [29,30], consistent with the induction of MS relapse by administration of IFN γ [31]. The increase in IL4-producing cells in the remission phase of MS patients may be a host defence mechanism. In our hands, fingolimod did not appear to down-regulate IL4-producing cells, which may be beneficial for Th1/Th17-mediated diseases like MS [1]. IL9-producing cells at pre-treatment may have been influenced by disease-modifying therapies such as IFN β [32], which was reported to potentiate IL9 production via IL21 in Th9-polarising conditions in humans [33]. However, as the MS patients without IFN β also had greater percentages of IL9-producing CD4⁺T and CD8⁺T cells, such increases may have some relevance to MS mechanisms. Although IL9 was previously regarded as one of the Th2 type cytokines, it was recently reported that IL9-producing CD4⁺T cells can induce neuroinflammation in certain conditions [34] and that Th17 cells can produce IL9, which exacerbates experimental autoimmune encephalomyelitis [35]. Therefore, increases in IL9-producing T cells in MS patients may warrant careful monitoring to clarify the relationship between IL9-producing T cell changes and relapse while on fingolimod therapy.

Finally, Treg and Ts are subpopulations of T cells that down-regulate immune response and autoimmune disease activities [36,37]. However, we did not find any differences in these cell percentages between the relapsed and non-relapsed MS patients during fingolimod therapy. Although the relative increases in these cells may have some roles in down-modulating the disease activity of MS during fingolimod treatment, these cell percentages are not useful as predictors of relapse.

Supporting Information

S1 Dataset. Actual values for percentages and counts of T cell subsets in healthy controls and patients with multiple sclerosis. (Sheet 1) The rows show the actual values for the percentages and counts of T cell subsets in individual samples. T cells are classified by their surface antigens. H1–H18 are healthy controls (HCs) and P1–P23 are patients with multiple sclerosis (MS). Figs 1, 2, 4, and S2 are based on these values. (Sheet 2) The rows show the actual values for the percentages and counts of T cell subsets in individual samples. T cells are classified by their cytokine productions. H1–H9 are HCs and P1–P16 are patients with MS. Figs 3, S3, and S4 are based on these values. The clinical statuses and timings of sample collection before or after induction of fingolimod treatment are also shown in each patient. EDSS = expanded disability status scale of Kurtzke; F = female; M = male; NT = not treated; WBC = white blood cells. (XLSX)

S1 Fig. Gating of cells in the flow cytometry studies. First, lymphocytes were gated as forward scatter-medium and side scatter-low populations (A), and CD4⁺T cells were gated as indicated in (B). The cells were then gated to discriminate central memory T cells (TCM), effector memory T cells (TEM), regulatory T cells (Treg), and suppressor precursor T cells (Ts). To determine the threshold for the CCR7⁺ and CCR7⁻ populations, we used a PE-conjugated mouse IgG1 isotype control (C). The cells were then separated by CD45RO and CCR7 to detect CCR7⁺CD45RO⁺ TCM, CCR7⁻CD45RO⁺ TEM, and CCR7⁺CD45RO⁻ naïve T cells (D). To determine the threshold for the CD25⁺ and CD25⁻ populations, we used a PE-conjugated mouse

IgG2b isotype control (E). The CD4⁺ populations were then separated by CD25 and CD127 to discriminate CD127^{low}CD25^{high} Treg (F). We also used an APC-conjugated mouse IgG1 isotype control (G) to determine the threshold for the CD28⁺ and CD28⁻ populations to separate CD4⁺CD28⁻ Ts (H).

(TIFF)

S2 Fig. The counts of T cell subsets are significantly decreased from 2 weeks. Effects of fingolimod on the absolute counts of phenotypically distinct CD4⁺T (A) and CD8⁺T (B) cell subpopulations in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. Naïve = naïve T cells (CCR7⁺CD45RO⁻); TCM = central memory T cells (CCR7⁺CD45RO⁺); TEM = effector memory T cells (CCR7⁻CD45RA⁻); Treg = regulatory T cells (CD4⁺CD25^{high}CD127^{low}); Ts = suppressor precursor T cells (CD28⁻); TEMRA = CD8⁺CD45RA⁺ effector memory T cells (CD8⁺CCR7⁻CD45RA⁺). The numbers analysed were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate the mean values. W = week; M = month. *** $p < 0.0001$, ** $p < 0.01$, * $p < 0.05$.

(TIFF)

S3 Fig. IFN γ -producing cells at pre-treatment are only significant in the MS patients without IFN β or corticosteroids. Percentages of IFN γ - (A), IL17- (B), IL9- (C), and IL4-producing (D) cells among CD4⁺T and CD8⁺T cells in MS patients with (MS PT+) and without (MS PT-) IFN β or corticosteroids within 3 months of the initiation of fingolimod. The numbers examined at each time point were: HC = 8, and MS PT- = 6, MS PT+ = 10. Box-whisker plots are shown.

(TIFF)

S4 Fig. The absolute counts of all cytokine-producing T cells in CD4⁺T cells are decreased from 2 weeks. Effects of fingolimod on the absolute counts of IFN γ - (A), IL17- (B), IL9- (C), and IL4-producing (D) cells in CD4⁺T and CD8⁺T cells in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. The numbers examined at each time point were: HC = 9, and MS PT = 16, 2W = 12, 1M = 12, 2M = 11, 3M = 12, 6M = 7, 12M = 11. The horizontal bars indicate the mean values. W = week; M = month. ** $p < 0.01$, * $p < 0.05$.

(TIFF)

Author Contributions

Conceived and designed the experiments: JK. Performed the experiments: ZYS. Analyzed the data: ZYS YK. Wrote the paper: ZYS RY YK TM JK. Revised the manuscript for content: KM. Collected data: ZYS RY YK SS KM SY DM TM HM.

References

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. *Nat Immunol*. 2007; 8: 913–919. PMID: [17712344](#)
2. Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. *Neurology*. 2011; 76 (Suppl 3): S9–14. doi: [10.1212/WNL.0b013e31820d9507](#) PMID: [21339490](#)
3. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. *Clin Neuropharmacol*. 2010; 33: 91–101. doi: [10.1097/WNF.0b013e3181cbf825](#) PMID: [20061941](#)
4. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. *Cell Mol Immunol*. 2005; 2: 439–48. PMID: [16426494](#)

5. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol*. 2004; 22: 745–763. PMID: [15032595](#)
6. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. *Neurology*. 2008; 71: 1261–1267. doi: [10.1212/01.wnl.0000327609.57688.ea](#) PMID: [18852441](#)
7. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, et al. FTY720 versus MMF with cyclosporine in *de novo* renal transplantation: a 1-year, randomized controlled trial in Europe and Australia. *Am J Transplant*. 2006; 6: 2912–21. PMID: [17061999](#)
8. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. *Neurology*. 2010; 75: 403–410. doi: [10.1212/WNL.0b013e3181ebdd64](#) PMID: [20592255](#)
9. Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. *J Neuroimmunol*. 2014; 268: 95–98. doi: [10.1016/j.jneuroim.2014.01.008](#) PMID: [24507619](#)
10. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6⁺ effector memory T cells. *J Immunol*. 2008; 180: 7948–7957. PMID: [18523258](#)
11. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol*. 2005; 58: 840–846. PMID: [16283615](#)
12. Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. *Brain*. 2007; 130: 1206–1223. PMID: [17439988](#)
13. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. *Mult Scler*. 2009; 15: 834–847. doi: [10.1177/1352458509104595](#) PMID: [19465451](#)
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology*. 1983; 33: 1444–1452. PMID: [6685237](#)
15. Poser S, Ritter G, Bauer HJ, Grosse-Wilde H, Kuwert EK, Raun NE. HLA-antigens and the prognosis of multiple sclerosis. *J Neurol*. 1981; 225: 219–221. PMID: [6167687](#)
16. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. *Mult Scler*. 2012; 18(9):1269–77. doi: [10.1177/1352458511435984](#) PMID: [22354739](#)
17. Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin-4 antibody status. *J Neurol Neurosurg Psychiatry*. 2013; 84: 29–34. doi: [10.1136/jnnp-2012-302925](#) PMID: [23038741](#)
18. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. *Mult Scler*. 2009; 15: 834–847. doi: [10.1177/1352458509104595](#) PMID: [19465451](#)
19. Cui YW, Kawano Y, Yamasaki R, Shi N, Masaki K, Isobe N, et al. Decreased CCR2 and CD62L expressions on peripheral blood classical monocytes in amyotrophic lateral sclerosis. *Clin Exp Neuroimmunol*. 2014; 5: 92–96.
20. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12-months: results of a phase 2 observational extension. *BMC Neurol*. 2014; 14: 21. doi: [10.1186/1471-2377-14-21](#) PMID: [24475777](#)
21. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. *Ann Neurol*. 2009; 65: 499–509. doi: [10.1002/ana.21652](#) PMID: [19475668](#)
22. Chiba K, Kataoka H, Seki N, Shimano K, Koyama M, Fukunari A, et al. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon- β in mouse experimental autoimmune encephalomyelitis. *Int Immunopharmacol*. 2011; 11: 366–372. doi: [10.1016/j.intimp.2010.10.005](#) PMID: [20955831](#)
23. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. *Mult Scler*. 2012; 18: 113–115. doi: [10.1177/1352458511431973](#) PMID: [22146605](#)
24. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. *Mult Scler*. 2012; 18: 1650–1652. doi: [10.1177/1352458512463768](#) PMID: [23100527](#)

25. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. *Neurology*. 2012; 79: 2000–2003. doi: [10.1212/WNL.0b013e3182735cb3](https://doi.org/10.1212/WNL.0b013e3182735cb3) PMID: [23035065](https://pubmed.ncbi.nlm.nih.gov/23035065/)
26. Ishizu T, Osoegawa M, Mei F-J, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. *Brain*. 2005; 128: 988–1002. PMID: [15743872](https://pubmed.ncbi.nlm.nih.gov/15743872/)
27. Tanaka M, Matsushita T, Tateishi T, Ochi H, Kawano Y, Mei FJ, et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. *Neurology*. 2008; 71: 974–981. doi: [10.1212/01.wnl.0000326589.57128.c3](https://doi.org/10.1212/01.wnl.0000326589.57128.c3) PMID: [18809833](https://pubmed.ncbi.nlm.nih.gov/18809833/)
28. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. *PLOS ONE*. 2013; 8(4): e61835. doi: [10.1371/journal.pone.0061835](https://doi.org/10.1371/journal.pone.0061835) PMID: [23637915](https://pubmed.ncbi.nlm.nih.gov/23637915/)
29. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. *J Neuroimmunol*. 2001; 119(2): 297–305. PMID: [11585633](https://pubmed.ncbi.nlm.nih.gov/11585633/)
30. Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. *Mult Scler*. 2001; 7(3): 145–50 PMID: [11475436](https://pubmed.ncbi.nlm.nih.gov/11475436/)
31. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. *Lancet*. 1987; 1(8538): 893–895. PMID: [2882294](https://pubmed.ncbi.nlm.nih.gov/2882294/)
32. Ochi H, Mei F-J, Osoegawa M, Minohara M, Murai H, Taniwaki T, et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. *J Neurol Sci*. 2004; 222: 65–73. PMID: [15240198](https://pubmed.ncbi.nlm.nih.gov/15240198/)
33. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. *Immunol Cell Biol*. 2010; 88: 624–631. doi: [10.1038/icb.2010.53](https://doi.org/10.1038/icb.2010.53) PMID: [20421880](https://pubmed.ncbi.nlm.nih.gov/20421880/)
34. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17 and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. *J Immunol*. 2009; 183: 7169–7177. doi: [10.4049/jimmunol.0901906](https://doi.org/10.4049/jimmunol.0901906) PMID: [19890056](https://pubmed.ncbi.nlm.nih.gov/19890056/)
35. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. *J Exp Med*. 2009; 206: 1653–1660. doi: [10.1084/jem.20090246](https://doi.org/10.1084/jem.20090246) PMID: [19596803](https://pubmed.ncbi.nlm.nih.gov/19596803/)
36. Putheti P, Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. *J Neuroimmunol*. 2003; 144: 125–131. PMID: [14597106](https://pubmed.ncbi.nlm.nih.gov/14597106/)
37. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. *Clin Diagn Lab Immunol*. 1995; 2: 249–252. PMID: [7697540](https://pubmed.ncbi.nlm.nih.gov/7697540/)